as of 03-20-2026 10:47am EST
Decoy Therapeutics Inc is a preclinical-stage biotechnology company developing peptide conjugate drug candidates using machine learning, artificial intelligence tools, and high-throughput synthesis techniques. The company's initial pipeline is focused on respiratory viruses and GI cancers.
Upcoming Earnings Alert:
Get ready for potential market movements as Decoy Therapeutics Inc. Common Stock (DCOY) prepares to release earnings report on 23 Mar 2026.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 4.7M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 67.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $0.53 - $9.09 | Next Earning Date: | 03-23-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
See how DCOY stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "DCOY Decoy Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.